Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Cancer Res ; 75(22): 4688-96, 2015 Nov 15.
Article in English | MEDLINE | ID: mdl-26432404

ABSTRACT

Clinical trials have established the benefit of androgen deprivation therapy (ADT) combined with radiotherapy in prostate cancer. ADT sensitizes prostate cancer to radiotherapy-induced death at least in part through inhibition of DNA repair machinery, but for unknown reasons, adjuvant ADT provides further survival benefits. Here, we show that androgen receptor (AR) expression and activity are durably upregulated following radiotherapy in multiple human prostate cancer models in vitro and in vivo. Moreover, the degree of AR upregulation correlates with survival in vitro and time to tumor progression in animal models. We also provide evidence of AR pathway upregulation, measured by a rise in serum levels of AR-regulated hK2 protein, in nearly 20% of patients after radiotherapy. Furthermore, these men were three-fold more likely to experience subsequent biochemical failure. Collectively, these data demonstrate that radiotherapy can upregulate AR signaling after therapy to an extent that negatively affects disease progression and/or survival.


Subject(s)
Prostatic Neoplasms/radiotherapy , Radiation Tolerance/physiology , Receptors, Androgen/biosynthesis , Animals , Blotting, Western , Cell Line, Tumor , Comet Assay , Fluorescent Antibody Technique , Humans , Luminescent Measurements , Male , Mice , Mice, SCID , Prostatic Neoplasms/metabolism , Real-Time Polymerase Chain Reaction , Up-Regulation , Xenograft Model Antitumor Assays
2.
Eur Urol ; 67(6): 1009-1016, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25308970

ABSTRACT

BACKGROUND: The management of biochemical failure (BF) following external beam radiotherapy (EBRT) for prostate cancer is controversial, due to both the heterogeneous disease course following a BF and a lack of clinical trials in this setting. OBJECTIVE: We sought to characterize the natural history and predictors of outcome for patients experiencing BF in a large cohort of men with localized prostate cancer undergoing definitive dose-escalated EBRT. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis included 2694 patients with localized prostate cancer treated with EBRT at a large academic center. Of these, 609 experienced BF, defined as prostate-specific antigen (PSA) nadir + 2 ng/ml. The median follow-up was 83 mo for all patients and 122 mo for BF patients. INTERVENTION(S): All patients received EBRT at doses of 75.6-86.4 Gy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary objective of this study was to determine predictors of distant progression at the time of BF. Cox proportional hazards models were used in univariate and multivariate analyses of distant metastases (DM), and a competing risks method was used to analyze prostate cancer-specific mortality (PCSM). RESULTS AND LIMITATIONS: From the date of BF, the median times to DM and PCSM mortality were 5.4 yr and 10.5 yr, respectively. Shorter posttreatment PSA doubling time, a higher initial clinical tumor stage, a higher pretreatment Gleason score, and a shorter interval from the end of radiotherapy to BF were independent predictors for clinical progression following BF. Patients with two of these risk factors had a significantly higher incidence of DM and PCSM following BF than those with zero or one risk factor. The main limitations of this study are its retrospective nature and heterogeneous salvage interventions. CONCLUSIONS: Clinical and pathologic factors can help identify patients at high risk of clinical progression following BF. PATIENT SUMMARY: In this report, we look at predictors of outcome for patients with prostate cancer recurrence, as determined by prostate-specific antigen (PSA) levels, following radiation treatment. We found that the approximate median times to distant metastasis and death from prostate cancer for patients in this situation were 5 yr and 10 yr, respectively. Furthermore, we found that patients with a rapid increase in PSA levels following treatment, a short time to PSA recurrence, invasion of extraprostatic organs, or a high Gleason score had worse outcomes.


Subject(s)
Neoplasm Recurrence, Local/radiotherapy , Prostate-Specific Antigen/blood , Prostatic Neoplasms/radiotherapy , Radiotherapy, Conformal/mortality , Aged , Disease-Free Survival , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Grading/statistics & numerical data , Neoplasm Recurrence, Local/blood , Neoplasm Recurrence, Local/mortality , Neoplasm Staging , Prostatic Neoplasms/mortality , Radiotherapy Dosage , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome
3.
BJU Int ; 114(3): 360-7, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24447404

ABSTRACT

OBJECTIVE: To compare tumour control and toxicity outcomes with the use of high-dose intensity-modulated radiation therapy (IMRT) alone or brachytherapy combined with IMRT (combo-RT) for patients with intermediate-risk prostate cancer. PATIENTS AND METHODS: Between 1997 and 2010, 870 consecutive patients with intermediate-risk prostate cancer were treated at our institution with either 86.4 Gy of IMRT alone (n = 470) or combo-RT consisting of brachytherapy combined with 50.4 Gy of IMRT (n = 400). Brachytherapy consisted of low-dose-rate permanent interstitial implantation in 260 patients and high-dose-rate temporary implantation in 140 patients. The median (range) follow-up for the entire cohort was 5.3 (1-14) years. RESULTS: For IMRT alone vs combo-RT, 7-year actuarial prostate-specific antigen (PSA)-relapse-free survival (PSA-RFS) rates were 81.4 vs 92.0% (P < 0.001), and distant metastases-free survival (DMFS) rates were 93.0 vs 97.2% (P = 0.04), respectively. Multivariate analysis showed that combo-RT was associated with better PSA-RFS (hazard ratio [HR], 0.40 [95% confidence interval, 0.24-0.66], P < 0.001), and better DMFS (HR, 0.41 [0.18-0.92], P = 0.03). A higher incidence of acute genitourinary (GU) grade 2 (35.8 vs 18.9%; P < 0.01) and acute GU grade 3 (2.3 vs 0.4%; P = 0.03) toxicities occurred in the combo-RT group than in the IMRT-alone group. Most acute toxicity resolved. Late toxicity outcomes were similar between the treatment groups. The 7-year actuarial late toxicity rates for grade 2 gastrointestinal (GI) toxicity were 4.6 vs 4.1% (P = 0.89), for grade 3 GI toxicity 0.4 vs 1.4% (P = 0.36), for grade 2 GU toxicity 19.4 vs 21.2% (P = 0.14), and grade 3 GU toxicity 3.1 vs 1.4% (P = 0.74) for the IMRT vs the combo-RT group, respectively. CONCLUSIONS: Enhanced dose escalation using combo-RT was associated with superior PSA-RFS and DMFS outcomes for patients with intermediate-risk prostate cancer compared with high-dose IMRT alone at a dose of 86.4 Gy. While acute GU toxicities were more prevalent in the combo-RT group, the incidence of late GI and GU toxicities was similar between the treatment groups.


Subject(s)
Brachytherapy , Neoplasm Recurrence, Local/radiotherapy , Prostatic Neoplasms/radiotherapy , Radiotherapy, Intensity-Modulated , Aged , Disease-Free Survival , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Prostate-Specific Antigen , Prostatic Neoplasms/mortality , Prostatic Neoplasms/pathology , Radiotherapy Dosage , Risk Assessment , Treatment Outcome
4.
Cancer Discov ; 3(11): 1245-53, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24027196

ABSTRACT

UNLABELLED: We demonstrate that the androgen receptor (AR) regulates a transcriptional program of DNA repair genes that promotes prostate cancer radioresistance, providing a potential mechanism by which androgen deprivation therapy synergizes with ionizing radiation. Using a model of castration-resistant prostate cancer, we show that second-generation antiandrogen therapy results in downregulation of DNA repair genes. Next, we demonstrate that primary prostate cancers display a significant spectrum of AR transcriptional output, which correlates with expression of a set of DNA repair genes. Using RNA-seq and ChIP-seq, we define which of these DNA repair genes are both induced by androgen and represent direct AR targets. We establish that prostate cancer cells treated with ionizing radiation plus androgen demonstrate enhanced DNA repair and decreased DNA damage and furthermore that antiandrogen treatment causes increased DNA damage and decreased clonogenic survival. Finally, we demonstrate that antiandrogen treatment results in decreased classical nonhomologous end-joining. SIGNIFICANCE: We demonstrate that the AR regulates a network of DNA repair genes, providing a potential mechanism by which androgen deprivation synergizes with radiotherapy for prostate cancer.


Subject(s)
DNA Repair , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms/drug therapy , Receptors, Androgen/metabolism , Androgen Antagonists/therapeutic use , Animals , Antineoplastic Agents, Hormonal/therapeutic use , Cell Line, Tumor , DNA Damage/radiation effects , Disease Models, Animal , Gene Expression Regulation, Neoplastic , Humans , Male , Metribolone/therapeutic use , Mice , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms, Castration-Resistant/metabolism , Prostatic Neoplasms, Castration-Resistant/radiotherapy , Radiation, Ionizing , Signal Transduction/genetics , Xenograft Model Antitumor Assays
5.
J Clin Oncol ; 31(23): 2936-41, 2013 Aug 10.
Article in English | MEDLINE | ID: mdl-23857975

ABSTRACT

PURPOSE: To compare event-free survival (EFS) in children with high-risk medulloblastoma randomly assigned to receive either chemotherapy before radiation or chemotherapy after radiation. PATIENTS AND METHODS: One hundred twelve patients were randomly assigned to each arm. Criteria used to categorize patients as high risk included M1-4 disease by modified Chang staging classification, T3b/T4 disease, or greater than 1.5 cm3 of residual tumor after surgery. Postoperatively, children with high-risk medulloblastoma were randomly assigned to two arms, either chemotherapy entailing three cycles of cisplatin and etoposide before radiation (chemotherapy first [CT1]) or the same chemotherapy regimen after radiation (radiation therapy first [RT1]). Both groups received consolidation chemotherapy consisting of vincristine and cyclophosphamide. RESULTS: The median follow-up time was 6.4 years. Five-year EFS was 66.0% in the CT1 arm and 70.0% in the RT1 arm (P = .54), and 5-year overall survival in the two groups was 73.1% and 76.1%, respectively (P = .47). In the CT1 arm, 40 of the 62 patients with residual disease achieved either complete or partial remission. CONCLUSION: Five-year EFS did not differ significantly whether, after surgery, patients received chemotherapy before or after radiotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cerebellar Neoplasms/drug therapy , Cerebellar Neoplasms/radiotherapy , Medulloblastoma/drug therapy , Medulloblastoma/radiotherapy , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cerebellar Neoplasms/pathology , Cerebellar Neoplasms/surgery , Chemoradiotherapy/methods , Child , Child, Preschool , Cisplatin/administration & dosage , Cisplatin/adverse effects , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Disease-Free Survival , Drug Administration Schedule , Etoposide/administration & dosage , Etoposide/adverse effects , Female , Humans , Male , Medulloblastoma/pathology , Medulloblastoma/surgery , Neoplasm Staging , Prognosis , Risk Factors , Vincristine/administration & dosage , Vincristine/adverse effects , Young Adult
6.
Int J Radiat Oncol Biol Phys ; 86(3): 529-33, 2013 Jul 01.
Article in English | MEDLINE | ID: mdl-23523323

ABSTRACT

PURPOSE: To determine whether the response to neoadjuvant androgen deprivation therapy (ADT) defined by a decline in prostate-specific antigen (PSA) to nadir values is associated with improved survival outcomes after external beam radiation therapy (EBRT) for prostate cancer. METHODS AND MATERIALS: One thousand forty-five patients with localized prostate cancer were treated with definitive EBRT in conjunction with neoadjuvant and concurrent ADT. A 6-month course of ADT was used (3 months during the neoadjuvant phase and 2 to 3 months concurrently with EBRT). The median EBRT prescription dose was 81 Gy using a conformal-based technique. The median follow-up time was 8.5 years. RESULTS: The 10-year PSA relapse-free survival outcome among patients with pre-radiation therapy PSA nadirs of ≤0.3 ng/mL was 74.3%, compared with 57.7% for patients with higher PSA nadir values (P<.001). The 10-year distant metastases-free survival outcome among patients with pre-radiation therapy PSA nadirs of ≤0.3 ng/mL was 86.1%, compared with 78.6% for patients with higher PSA nadir values (P=.004). In a competing-risk analysis, prostate cancer-related deaths were also significantly reduced among patients with pre-radiation therapy PSA nadirs of <0.3 ng/mL compared with higher values (7.8% compared with 13.7%; P=.009). Multivariable analysis demonstrated that the pre-EBRT PSA nadir value was a significant predictor of long-term biochemical tumor control, distant metastases-free survival, and cause-specific survival outcomes. CONCLUSIONS: Pre-radiation therapy nadir PSA values of ≤0.3 ng/mL after neoadjuvant ADT were associated with improved long-term biochemical tumor control, reduction in distant metastases, and prostate cancer-related death. Patients with higher nadir values may require alternative adjuvant therapies to improve outcomes.


Subject(s)
Androgen Antagonists/therapeutic use , Prostate-Specific Antigen/blood , Prostatic Neoplasms , Aged , Anilides/therapeutic use , Antineoplastic Agents/therapeutic use , Disease-Free Survival , Gonadotropin-Releasing Hormone/therapeutic use , Humans , Male , Middle Aged , Neoadjuvant Therapy/methods , Neoadjuvant Therapy/mortality , Nitriles/therapeutic use , Proportional Hazards Models , Prostatic Neoplasms/blood , Prostatic Neoplasms/mortality , Prostatic Neoplasms/pathology , Prostatic Neoplasms/therapy , Radiation Tolerance , Radiotherapy, Conformal , Retrospective Studies , Tosyl Compounds/therapeutic use , Treatment Outcome
7.
Rep Pract Oncol Radiother ; 18(6): 333-7, 2013 Nov 11.
Article in English | MEDLINE | ID: mdl-24416574

ABSTRACT

There have been significant improvements in the radiotherapeutic management of patients with high risk prostate cancer. Randomized trials have clearly demonstrated improved outcomes with the combination of radiotherapy in conjunction with androgen deprivation. While these trials have utilized low doses of radiotherapy in the range of 70 Gy, recent studies have suggested that significant benefits of combined androgen deprivation therapy with dose escalated radiotherapy are also observed. The use of high radiation dose levels in the setting of high risk prostate cancer is important, and strategies which combine external beam radiotherapy with a brachytherapy boost may provide an opportunity for even greater intensification of the radiation dose to the prostate target. Systemic therapies, second generation anti-androgen therapy and novel targeted agents integrated with radiotherapy will open up new vistas and challenges for further improved outcomes in patients with high-risk disease.

8.
Int J Radiat Oncol Biol Phys ; 81(3): e15-20, 2011 Nov 01.
Article in English | MEDLINE | ID: mdl-21481547

ABSTRACT

PURPOSE: We previously reported excellent local control for treating medulloblastoma with a limited boost to the tumor bed. In order to decrease ototoxicity, we subsequently implemented a tumor-bed boost using intensity-modulated radiation therapy (IMRT), the clinical results of which we report here. PATIENTS AND METHODS: A total of 33 patients with newly diagnosed medulloblastoma, 25 with standard risk, and 8 with high risk, were treated on an IMRT tumor-bed boost following craniospinal irradiation (CSI). Six standard-risk patients were treated with an institutional protocol with 18 Gy CSI in conjunction with intrathecal iodine-131-labeled monoclonal antibody. The majority of patients received concurrent vincristine and standard adjuvant chemotherapy. Pure-tone audiograms were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. RESULTS: Median age was 9 years old (range, 4-46 years old). Median follow-up was 63 months. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) rates for standard-risk patients who received 23.4 or 36 Gy CSI (not including those who received 18 Gy CSI with radioimmunotherapy) were 81.4% and 88.4%, respectively, at 5 years; 5-year PFS and OS rates for high-risk patients were both 87.5%. There were no isolated posterior fossa failures outside of the boost volume. Posttreatment audiograms were available for 31 patients, of whom 6%, at a median follow-up of 19 months, had developed Grade 3 hearing loss. CONCLUSION: An IMRT tumor-bed boost results in excellent local control while delivering a low mean dose to the cochlea, resulting in a low rate of ototoxicity.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Cerebellar Neoplasms/radiotherapy , Cochlea/radiation effects , Iodine Radioisotopes/therapeutic use , Medulloblastoma/radiotherapy , Radiotherapy, Intensity-Modulated/adverse effects , Adolescent , Adult , Cerebellar Neoplasms/drug therapy , Cerebellar Neoplasms/mortality , Chemotherapy, Adjuvant/methods , Child , Child, Preschool , Cranial Irradiation/methods , Disease-Free Survival , Female , Follow-Up Studies , Hearing/physiology , Hearing/radiation effects , Humans , Male , Medulloblastoma/drug therapy , Medulloblastoma/mortality , Middle Aged , New York City , Radioimmunotherapy/methods , Radiotherapy Dosage , Radiotherapy, Intensity-Modulated/methods , Retrospective Studies , Young Adult
9.
Nat Clin Pract Oncol ; 4(5): 295-304, 2007 May.
Article in English | MEDLINE | ID: mdl-17464337

ABSTRACT

Medulloblastoma is the most common brain malignancy in children and tremendous advances have recently been made in understanding the pathogenesis of this tumor. The Hedgehog and Wingless signaling pathways are implicated in medulloblastoma development, and both pathways were discovered as a result of analyses of genetic syndromes associated with the tumor. Over the past 80 years, considerable progress has been made in the treatment of what was once a fatal disease. The first survival reports followed the introduction of craniospinal irradiation, and yet the success of this modality, which continues to be a central component of treatment regimens for patients older than 3 years, comes at a significant cost. The present challenge in medulloblastoma treatment is to improve upon existing survival rates and to minimize the side effects of treatment. The current tools of clinical risk assessment fail to adequately identify patients older than 3 years who require less radiation and those who require more radiation. Significant effort has been made to improve clinical risk stratification and titration of treatment by analyzing properties of the tumor cells themselves for prognostic significance. These efforts include identifying histopathologic, cytogenetic, and molecular features that may correlate with prognosis.


Subject(s)
Cerebellar Neoplasms/pathology , Cerebellar Neoplasms/therapy , Medulloblastoma/pathology , Medulloblastoma/therapy , Neoplasm Staging , Biomarkers, Tumor , Cell Transformation, Neoplastic , Cerebellar Neoplasms/genetics , Child , Cytogenetics , Humans , Medulloblastoma/genetics , Prognosis , Risk Assessment , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...